Rongze Lu, PhD

Title(s)Associate Professor, Neurological Surgery
SchoolSchool of Medicine
Address1450 Third Street, #482
San Francisco CA 94158
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    City of Hope , Duarte, CAPh.D.06/2011Cancer Immunology
    Collapse Awards and Honors
    Department of Defense2020DOD Peer Reviewed Cancer Research Program Career Development Award
    Keystone Conference2020Keystone Early Career Investigator Award
    City of Hope2008H.N. and Frances C. Berger Foundation Fellowship

    Collapse Overview 
    Collapse Overview
    I am an Associate Professor in the Department of Neurological Surgery at University of California, San Francisco (UCSF). Our lab focuses on identifying molecular mechanisms mediating immune suppression and evasion in brain tumors, with the goal of developing novel immunotherapeutics for these diseases. My recent research identified that protein phosphatase 2A negatively regulated T cell and macrophage mediated anti-tumor immunity, and further demonstrated that pharmacological inhibition of PP2A synergized with PD-1 blockade in multiple type of resistant tumors including glioblastoma. Based on those findings, a Phase I/II trial (NCT03027388) of PP2A inhibitor in recurrent glioblastoma is ongoing.
    Collapse Websites

    Collapse Research 
    Collapse Research Activities and Funding
    Regulation of Macrophage- and Microglia-mediated STING Signaling in Glioblastoma
    NIH/NINDS RO1NS126501Sep 1, 2022 - Aug 31, 2027
    Role: Principal Investigator
    Novel Strategy to Target PP2A
    NIH SPORE Developmental Research Program Award Sep 1, 2022 - Aug 31, 2023
    Role: PI
    Focused Ultrasound Induced Optogenetic Activation of CAR-Macrophage for Glioblastoma
    MDAnderson-UT Austin Collaborative Pilot Project Grant Oct 1, 2021 - Sep 30, 2022
    Role: Principal Investigator
    Role of Aberrant Translational Quality Control in Tumorigenesis in Glioblastoma
    Cancer Prevention and Research Institute of Texas RP210068Sep 1, 2021 - Sep 1, 2023
    Role: Principal Investigator
    Targeting Protein Phosphatase 2A (PP2A) to Overcome Macrophage-Mediated Immunosuppression in Glioblastoma
    DOD PRCRP W81XWH-20-1-0428Jul 15, 2020 - Jul 15, 2024
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING-Type I Interferon Signaling in Glioblastoma. Cancer Research. 2023. Mondal I, Das O, Sun R, Gao J, Yu B, Diaz A, Behnan J, Dubey A, Meng Z, Eskandar E, Xu B, Lu R*, and Ho W* corresponding author.
    2. PP2A/STRN4 Negatively Regulates STING-Type I Interferon Signaling in Tumor Associated Macrophages. Journal of Clinical Investigation. 2023. Ho WS*, Mondal I*, Xu B*, Das O*, Sun R, Chiou P, Lyu J, Li L, Cai X, Tahmasebinia F, Wu C Y-J, Wu Z, Matsui W, Lim M, Meng Z, Lu RO* corresponding author.
    3. Pantothenate kinase 2 interacts with PINK1 to regulate mitochondrial quality control via acetyl-CoA metabolism. Nat Commun. 2022 05 03; 13(1):2412. Huang Y, Wan Z, Tang Y, Xu J, Laboret B, Nallamothu S, Yang C, Liu B, Lu RO, Lu RO, Lu B, Feng J, Cao J, Hayflick S, Wu Z, Zhou B. PMID: 35504872; PMCID: PMC9065001.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    4. Targeting Mitochondrial Oxidative Phosphorylation in Glioblastoma Therapy. Neuromolecular Med. 2022 03; 24(1):18-22. Wu Z, Ho WS, Lu R. PMID: 34487301.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    5. Mitochondrial Dysfunction, Macrophage, and Microglia in Brain Cancer. Front Cell Dev Biol. 2020; 8:620788. Lu RO, Ho WS. PMID: 33520994; PMCID: PMC7843701.
      View in: PubMed   Mentions: 9  
    6. Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma. J Neurooncol. 2020; 2(148):231-244. Maggio D, Ho WS, Breese R, Walbridge S, Wang H, Cui J, Heiss JD, Gilbert MR, Kovach JS, Lu RO*, Zhuang Z. corresponding author.
    7. Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. Nat Commun. 2019; 1(9):2126. Ho WS, Wang H, Maggio D, Kovach JS, Zhang Q, Song Q, Marincola FM, Heiss JD, Gilbert MR, Lu R* corresponding author.
    8. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019 05 22; 7(1):131. Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Group. PMID: 31113486; PMCID: PMC6529999.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimals
    9. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). J Immunother Cancer. 2018 06 22; 6(1):63. Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I, Wallden B, Marincola FM, Cesano A. PMID: 29929551; PMCID: PMC6013904.
      View in: PubMed   Mentions: 199     Fields:    Translation:HumansCells
    10. Immune oncology, immune responsiveness and the theory of everything. J Immunother Cancer. 2018 06 05; 6(1):50. Turan T, Kannan D, Patel M, Matthew Barnes J, Tanlimco SG, Lu R, Halliwill K, Kongpachith S, Kline DE, Hendrickx W, Cesano A, Butterfield LH, Kaufman HL, Hudson TJ, Bedognetti D, Marincola F, Samayoa J. PMID: 29871670; PMCID: PMC5989400.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    11. Cancer immune resistance: can theories converge? Emerg Top Life Sci. 2017 Dec 12; 1(5):411-419. Lu R, Turan T, Samayoa J, Marincola FM. PMID: 33525800; PMCID: PMC7289003.
      View in: PubMed   Mentions: 9     Fields:    
    12. LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation. Cancer Lett. 2018 02 28; 415:217-226. Ho WS, Sizdahkhani S, Hao S, Song H, Seldomridge A, Tandle A, Maric D, Kramp T, Lu R, Heiss JD, Camphausen K, Gilbert MR, Zhuang Z, Park DM. PMID: 29199006; PMCID: PMC5748254.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    13. Deubiquitinase DUBA is a post-translational brake on interleukin-17 production in T cells. Nature. 2015 Feb 19; 518(7539):417-21. Rutz S, Kayagaki N, Phung QT, Eidenschenk C, Noubade R, Wang X, Lesch J, Lu R, Newton K, Huang OW, Cochran AG, Vasser M, Fauber BP, DeVoss J, Webster J, Diehl L, Modrusan Z, Kirkpatrick DS, Lill JR, Ouyang W, Dixit VM. PMID: 25470037.
      View in: PubMed   Mentions: 69     Fields:    Translation:AnimalsCells
    14. NRROS negatively regulates reactive oxygen species during host defence and autoimmunity. Nature. 2014 May 08; 509(7499):235-9. Noubade R, Wong K, Ota N, Rutz S, Eidenschenk C, Valdez PA, Ding J, Peng I, Sebrell A, Caplazi P, DeVoss J, Soriano RH, Sai T, Lu R, Modrusan Z, Hackney J, Ouyang W. PMID: 24739962.
      View in: PubMed   Mentions: 102     Fields:    Translation:AnimalsCells
    15. G-protein-coupled receptor agonist BV8/prokineticin-2 and STAT3 protein form a feed-forward loop in both normal and malignant myeloid cells. J Biol Chem. 2013 May 10; 288(19):13842-9. Xin H, Lu R, Lee H, Zhang W, Zhang C, Deng J, Liu Y, Shen S, Wagner KU, Forman S, Jove R, Yu H. PMID: 23548897; PMCID: PMC3650420.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    16. CEACAM1 negatively regulates IL-1β production in LPS activated neutrophils by recruiting SHP-1 to a SYK-TLR4-CEACAM1 complex. PLoS Pathog. 2012; 8(4):e1002597. Lu R, Pan H, Shively JE. PMID: 22496641; PMCID: PMC3320586.
      View in: PubMed   Mentions: 43     Fields:    Translation:AnimalsCells
    17. Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. Cancer Res. 2012 May 01; 72(9):2239-50. Lu R, Kujawski M, Pan H, Shively JE. PMID: 22406619; PMCID: PMC3765079.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    18. Interaction of actin with carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) receptor in liposomes is Ca2+- and phospholipid-dependent. J Biol Chem. 2011 Aug 05; 286(31):27528-36. Lu R, Niesen MJ, Hu W, Vaidehi N, Shively JE. PMID: 21669871; PMCID: PMC3149345.
      View in: PubMed   Mentions: 7     Fields:    Translation:Cells